TWI674097B - 磷酸酯衍生物之調配物 - Google Patents

磷酸酯衍生物之調配物 Download PDF

Info

Publication number
TWI674097B
TWI674097B TW104120487A TW104120487A TWI674097B TW I674097 B TWI674097 B TW I674097B TW 104120487 A TW104120487 A TW 104120487A TW 104120487 A TW104120487 A TW 104120487A TW I674097 B TWI674097 B TW I674097B
Authority
TW
Taiwan
Prior art keywords
formulation
volume
phosphate
gemcitabine
benzyloxy
Prior art date
Application number
TW104120487A
Other languages
English (en)
Chinese (zh)
Other versions
TW201613611A (en
Inventor
胡格 葛瑞福斯
喬登 肯諾芬
Original Assignee
英商努卡那公眾有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1411253.6A external-priority patent/GB201411253D0/en
Priority claimed from GBGB1417646.5A external-priority patent/GB201417646D0/en
Application filed by 英商努卡那公眾有限公司 filed Critical 英商努卡那公眾有限公司
Publication of TW201613611A publication Critical patent/TW201613611A/zh
Application granted granted Critical
Publication of TWI674097B publication Critical patent/TWI674097B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
TW104120487A 2014-06-25 2015-06-25 磷酸酯衍生物之調配物 TWI674097B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IN2050/MUM/2014 2014-06-25
??GB1411253.6 2014-06-25
GBGB1411253.6A GB201411253D0 (en) 2014-06-25 2014-06-25 Prodrug
IN2050MU2014 2014-06-25
??GB1417646.5 2014-10-06
GBGB1417646.5A GB201417646D0 (en) 2014-10-06 2014-10-06 Formulations of phosphate derivatives

Publications (2)

Publication Number Publication Date
TW201613611A TW201613611A (en) 2016-04-16
TWI674097B true TWI674097B (zh) 2019-10-11

Family

ID=53499028

Family Applications (2)

Application Number Title Priority Date Filing Date
TW104120487A TWI674097B (zh) 2014-06-25 2015-06-25 磷酸酯衍生物之調配物
TW108132019A TWI765176B (zh) 2014-06-25 2015-06-25 磷酸酯衍生物之調配物

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW108132019A TWI765176B (zh) 2014-06-25 2015-06-25 磷酸酯衍生物之調配物

Country Status (30)

Country Link
US (4) US10117888B2 (enExample)
EP (2) EP3119794B1 (enExample)
JP (3) JP6855248B2 (enExample)
KR (2) KR20220104270A (enExample)
CN (2) CN110882268A (enExample)
AU (2) AU2015278900B2 (enExample)
BR (1) BR112016025787B1 (enExample)
CA (1) CA2944966C (enExample)
CL (1) CL2016003261A1 (enExample)
CY (1) CY1119772T1 (enExample)
DK (1) DK3119794T3 (enExample)
EA (1) EA033046B1 (enExample)
ES (1) ES2655820T3 (enExample)
HK (1) HK1244437A1 (enExample)
HR (1) HRP20180007T1 (enExample)
HU (1) HUE036011T2 (enExample)
IL (2) IL248345B (enExample)
LT (1) LT3119794T (enExample)
MX (2) MX373942B (enExample)
MY (1) MY186584A (enExample)
NO (1) NO3119794T3 (enExample)
PH (1) PH12016502552A1 (enExample)
PL (1) PL3119794T3 (enExample)
PT (1) PT3119794T (enExample)
RS (1) RS56752B1 (enExample)
SG (1) SG11201608809RA (enExample)
SI (1) SI3119794T1 (enExample)
SM (1) SMT201800041T1 (enExample)
TW (2) TWI674097B (enExample)
WO (1) WO2015198059A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
EP3447061B1 (en) 2011-03-01 2021-11-24 NuCana plc Pharmaceutical formulation comprising a phosphoramidate derivative of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer
AU2013346515B2 (en) 2012-11-16 2017-05-25 NuCana plc Process for preparing nucleoside prodrugs
NO3119794T3 (enExample) 2014-06-25 2018-03-10
MY183198A (en) * 2014-06-25 2021-02-18 Nucana Biomed Ltd Gemcitabine prodrugs
GB201417644D0 (en) * 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
EA031727B1 (ru) 2014-11-28 2019-02-28 НУКАНА ПиЭлСи Новые производные 2'- и/или 5'-аминокислотных эфиров фосфороамидатов 3'-дезоксиаденозина в качестве противораковых соединений
CN106478753A (zh) * 2015-09-16 2017-03-08 博瑞生物医药（苏州）股份有限公司 一种nuc‑1031单一异构体的制备方法和用途
CN106543252A (zh) * 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 核苷氨基磷酸酯类前药的制备方法及其中间体
CN106543220A (zh) 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 氨基磷酸酯化合物及其制备方法和晶体
MX385837B (es) 2015-10-05 2025-03-18 NuCana plc Terapia de combinacion.
KR20180101370A (ko) 2015-12-11 2018-09-12 뉴카나 피엘씨 인산염 유도체 및 젬시타빈 전구약물 nuc-1031의 부분입체 이성질체 선별적 합성
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609600D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
CN110035740B (zh) 2016-11-02 2023-08-04 中枢疗法公司 稳定的水性辣椒素可注射制剂及其医学用途
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
CA3069540A1 (en) 2017-07-20 2019-01-24 Centrexion Therapeutics Corporation Methods and compositions for treatment of pain using capsaicin
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis
CN109956986B (zh) 2017-12-22 2021-04-27 浙江柏拉阿图医药科技有限公司 肝递送吉西他滨前体药物核苷环磷酸酯化合物及应用
WO2023076878A1 (en) * 2021-10-26 2023-05-04 Emphascience Inc. Ready-to-dilute formulation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005012327A2 (en) * 2003-07-21 2005-02-10 University College Cardiff Consultants Limited Nucleotide phosphoramidates as anticancer agents

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
WO1999037753A1 (en) 1998-01-23 1999-07-29 Newbiotics, Inc. Enzyme catalyzed therapeutic agents
CN1390227A (zh) 1999-07-22 2003-01-08 新生物生物公司 酶催化的治疗活化
CN1181829C (zh) * 2000-11-03 2004-12-29 中国人民解放军军事医学科学院附属医院 吉西他滨溶液制剂
CA2595606C (en) 2005-01-27 2014-12-16 Erimos Pharmaceuticals Llc Oral formulations for delivery of catecholic butanes including ndga compounds
CA2635797C (en) * 2006-02-09 2015-03-31 Macusight, Inc. Stable formulations, and methods of their preparation and use
EP1913962A1 (en) * 2006-10-22 2008-04-23 Ophir Perelson Expandable medical device for the treatment and prevention of cardiovascular diseases
WO2011008985A2 (en) 2009-07-15 2011-01-20 Georgia Tech Research Corporation Methods and compositions for improved delivery of therapeutic and diagnostic agents
MX2012005677A (es) * 2009-11-20 2012-08-23 Clavis Pharma Asa Formulaciones parentales de derivados de gemcitabina.
CN101926757B (zh) * 2010-09-01 2013-01-02 北京大学 一种难溶性药物的液体组合物及其制备方法
KR101231925B1 (ko) * 2010-10-27 2013-02-08 씨제이제일제당 (주) 젬시타빈의 전구약물 및 이의 제조방법
US9107943B2 (en) * 2012-01-20 2015-08-18 Aratana Therapeutics Nv Eye drop composition
WO2014074725A1 (en) 2012-11-07 2014-05-15 Ohio State Innovation Foundation Substituted gemcitabine aryl amide analogs
AU2013346515B2 (en) 2012-11-16 2017-05-25 NuCana plc Process for preparing nucleoside prodrugs
KR20160099090A (ko) 2013-11-27 2016-08-19 아이데닉스 파마슈티칼스 엘엘씨 간암의 치료를 위한 뉴클레오티드
MY183198A (en) 2014-06-25 2021-02-18 Nucana Biomed Ltd Gemcitabine prodrugs
NO3119794T3 (enExample) 2014-06-25 2018-03-10
CN106795198B (zh) 2014-07-22 2019-09-06 努卡那公共有限公司 用于制备吉西他滨-[苯基(苄氧基-l-丙氨酸基)]磷酸酯的方法
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
TR201806642T4 (tr) 2015-05-14 2018-06-21 NuCana plc Kanser tedavileri.
MX385837B (es) 2015-10-05 2025-03-18 NuCana plc Terapia de combinacion.
KR20180101370A (ko) 2015-12-11 2018-09-12 뉴카나 피엘씨 인산염 유도체 및 젬시타빈 전구약물 nuc-1031의 부분입체 이성질체 선별적 합성
WO2017109486A1 (en) 2015-12-23 2017-06-29 Nucana Biomed Limited Combination therapy
AU2015418015B2 (en) 2015-12-23 2021-12-09 NuCana plc Combination therapy
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005012327A2 (en) * 2003-07-21 2005-02-10 University College Cardiff Consultants Limited Nucleotide phosphoramidates as anticancer agents

Also Published As

Publication number Publication date
CL2016003261A1 (es) 2017-10-06
JP2022031659A (ja) 2022-02-22
US11040051B2 (en) 2021-06-22
DK3119794T3 (en) 2018-01-22
KR102421929B1 (ko) 2022-07-15
IL248345B (en) 2020-10-29
IL276199A (en) 2020-09-30
LT3119794T (lt) 2018-02-12
TWI765176B (zh) 2022-05-21
AU2015278900B2 (en) 2019-04-04
MY186584A (en) 2021-07-28
SMT201800041T1 (it) 2018-03-08
RS56752B1 (sr) 2018-04-30
JP2017519022A (ja) 2017-07-13
ES2655820T3 (es) 2018-02-21
US20190022118A1 (en) 2019-01-24
CA2944966A1 (en) 2015-12-30
MX2020004054A (es) 2021-11-30
BR112016025787A2 (pt) 2017-08-15
CN106470672A (zh) 2017-03-01
PH12016502552A1 (en) 2017-04-10
US20220031727A1 (en) 2022-02-03
MX2016015629A (es) 2017-08-02
WO2015198059A1 (en) 2015-12-30
SI3119794T1 (en) 2018-02-28
CY1119772T1 (el) 2018-06-27
US11707477B2 (en) 2023-07-25
MX388313B (es) 2025-03-19
AU2015278900A1 (en) 2016-10-27
JP6970221B2 (ja) 2021-11-24
JP6855248B2 (ja) 2021-04-07
HRP20180007T1 (hr) 2018-02-23
TW201613611A (en) 2016-04-16
EP3119794B1 (en) 2017-10-11
EA201692422A1 (ru) 2017-04-28
BR112016025787B1 (pt) 2022-12-13
IL248345A0 (en) 2016-11-30
JP7329025B2 (ja) 2023-08-17
JP2020079255A (ja) 2020-05-28
US20170095498A1 (en) 2017-04-06
KR20220104270A (ko) 2022-07-26
EP3119794A1 (en) 2017-01-25
AU2019204557A1 (en) 2019-07-18
IL276199B (en) 2022-04-01
PL3119794T3 (pl) 2018-04-30
EP3269391A1 (en) 2018-01-17
HK1244437A1 (en) 2018-08-10
CN110882268A (zh) 2020-03-17
MX373942B (es) 2020-07-13
KR20170042501A (ko) 2017-04-19
EA033046B1 (ru) 2019-08-30
NO3119794T3 (enExample) 2018-03-10
TW201945007A (zh) 2019-12-01
US20200397810A1 (en) 2020-12-24
US10117888B2 (en) 2018-11-06
PT3119794T (pt) 2018-01-15
HUE036011T2 (hu) 2018-06-28
CA2944966C (en) 2022-10-25
AU2019204557B2 (en) 2020-08-27
NZ725009A (en) 2021-02-26
CN106470672B (zh) 2019-11-05
SG11201608809RA (en) 2016-11-29
US10786523B2 (en) 2020-09-29

Similar Documents

Publication Publication Date Title
TWI674097B (zh) 磷酸酯衍生物之調配物
US20250302859A1 (en) Formulations of phosphoramidate derivatives of nucleoside drugs
HK1227880A1 (en) Formulation comprising a gemcitabine-prodrug
HK1227880B (en) Formulation comprising a gemcitabine-prodrug
NZ725009B2 (en) Formulation comprising a gemcitabine-prodrug
EA042714B1 (ru) Состав, содержащий пролекарство гемцитабина
NZ743479A (en) Formulations of phosphoramidate derivatives of nucleoside drugs

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees